All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 76 points (0.5%) at 15,300 as of Tuesday, July 9, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 2,101 issues advancing vs. 849 declining with 106 unchanged. The Health Care sector currently sits down 0.3% versus the S&P 500, which is up 1.2%. On the negative front, top decliners within the sector include Intuitive Surgical ( ISRG), down 17.9%, Quest Diagnostics ( DGX), down 5.2%, Laboratory Corporation of America Holdings ( LH), down 4.3% and Abbott Laboratories ( ABT), down 0.9%. Top gainers within the sector include Regeneron Pharmaceuticals ( REGN), up 2.1%, Celgene Corporation ( CELG), up 1.9%, WellPoint ( WLP), up 1.6%, Cigna ( CI), up 1.5% and Alexion Pharmaceuticals ( ALXN), up 1.5%. TheStreet would like to highlight 4 stocks pushing the sector lower today: 4. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector lower today. As of noon trading, Novo Nordisk A/S is down $2.04 (-1.3%) to $158.71 on light volume. Thus far, 92,050 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 300,200 shares. The stock has ranged in price between $158.17-$160.19 after having opened the day at $159.22 as compared to the previous trading day's close of $160.75. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $88.0 billion and is part of the drugs industry. Shares are down 1.5% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.